Stage IIIA squamous lung cancer with pathologic complete response after immunochemotherapy

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: PD-L1 TPS 90%; PD-L1 CPS 100%; EGFR p.G719S 24.9%; EGFR p.S768I 24.6%; TP53 p.S183* 7.2%; TMB 0.0 Muts/Mb

Systematic imaging in March 2025 showed no recurrence or metastasis, with postoperative disease-free survival longer than 30 months and overall survival longer than 34 months.

PubMed CentralRead more →

Stage IVA lung adenosquamous carcinoma: complete response after paclitaxel, nedaplatin, and tislelizumab

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Adenosquamous lung cancer markers; PD-L1 TPS 18%; KRAS, BRAF, PIK3CA, FLT1 mutation; TMB 3.7

Metastatic Site: pleura/chest wall, cervical lymph nodes, axillary…

As of March 30, 2025, he maintained complete response with normal tumor markers, no radiologic evidence of progression or recurrence, and progression-free survival of 46.5 months after paclitaxel/nedaplatin/tislelizumab followed by maintenance tislelizumab.

PubMed CentralRead more →

Stage II EGFR Lung Cancer: Samantha's Patient Story

Patient Info: Samantha Vaughn, Female | Stage II

Biomarkers: EGFR mutation

Samantha had Stage II EGFR-mutated lung cancer removed surgically and was receiving post-operative daily Tagrisso through a clinical trial. As of June 2025, she reported clear results so far but remained on active targeted therapy.

The Patient StoryRead more →

Stage III Lung Cancer: Alexis's Survivor Story

Patient Info: Alexis, Female, Under 40 | Stage III

Biomarkers: No lung tumor biomarker reported

Alexis had Stage III pulmonary neuroendocrine/carcinoid cancer treated with removal of the entire left lung and 4 months of adjuvant pill chemotherapy. Follow-up scans after chemotherapy were clear, and her doctor called the status no evidence of disease; she continues long-term surveillance.

The Patient StoryRead more →

Stage I Pleomorphic Lung Cancer Recurring With Bone Metastasis Within Five Months

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 high; no detected driver mutation

Metastatic Site: bone

PET-CT in December 2024 showed a partial response. As of February 2025, he remained on sintilimab and bevacizumab maintenance with about 9 months of progression-free survival after recurrence treatment.

PubMed CentralRead more →

ALK-rearranged lung adenocarcinoma: sustained partial response on reduced-dose crizotinib after renal cysts

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: ALK gene translocation positive in >15% of tumor cells by FISH

As of June 2025, the lung cancer remained in partial response without progression on reduced-dose crizotinib, while crizotinib-associated renal cysts had markedly regressed.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Alisa's Patient Story

Patient Info: Alisa Secaida, Female, Under 40 | Stage IV

Biomarkers: ALK-positive / ALK-rearranged

Metastatic Site: Brain; lymph nodes

As of May 2025, after alectinib and lung surgery, pathology still showed active tumor and lymph-node cancer cells, and Alisa was receiving IMRT for remaining disease.

City of HopeRead more →

Poorly Differentiated Lung Adenocarcinoma Recurring After Surgery and Chemotherapy

Patient Info: Anonymized, male, 60s

Biomarkers: No driver mutation identified initially; recurrent tumor PD-L1 >50%

The cancer recurred in June 2024 with a para-aortic mass and enlarged mediastinal and supraclavicular lymph nodes. Camrelizumab was started, but he could not tolerate it and declined further treatment.

PubMed CentralRead more →

Poorly Differentiated Lung Adenocarcinoma Without Recurrence After Surgery and Chemotherapy

Patient Info: Anonymized, male, 60s

Biomarkers: No driver mutation identified; PD-L1 at least 1%

No signs of recurrence were observed through April 2025 after surgery and 4 cycles of adjuvant chemotherapy.

PubMed CentralRead more →

Localized sarcomatoid lung carcinoma: no recurrence 14 months after lobectomy

Patient Info: Anonymized, Male, 50s

Biomarkers: No molecular biomarkers reported; histopathology confirmed sarcomatoid carcinoma

As of May 2025, the patient remained in good health with no evidence of recurrence 14 months after video-assisted thoracoscopic left lower lobectomy.

PubMed CentralRead more →

Localized lung neuroendocrine tumor/carcinoid: wedge resection after surveillance

Patient Info: Anonymized, Female, 50s

Biomarkers: Well-differentiated neuroendocrine tumor, grade I; no lung molecular biomarkers reported

As of May 2025, the localized left lung carcinoid had remained stable during surveillance and was removed by thoracotomy with wedge resection; no lung metastasis was reported.

PubMed CentralRead more →

How We Got Here: 6 Young Lung Cancer Patients & Their Paths To Surgery- Part 1

Patient Info: Leah Phillips, Female | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: bone (pelvis; spine; ribs)

As of April 2025, Leah was living with Stage IV EGFR exon 19 deletion lung cancer while continuing Tagrisso after SBRT and right middle lobe lobectomy.

YouTube (JA search)Read more →

Preoperative Stage IIB lung adenocarcinoma: no recurrence after robotic surgery

Patient Info: Anonymized, Female, 60s

As of April 2025, 6-month chest CT showed no recurrence after robotic right lower lobectomy and mediastinal lymph node dissection; no additional chemotherapy or radiation was reported.

PubMed CentralRead more →

Synchronous Stage I lung adenocarcinomas: VATS surgery with clear margins

Patient Info: Anonymized, Male, 70+

He completed surgical treatment with negative lymph nodes and clear margins, was discharged on postoperative day 9, and was planned for surveillance with his respiratory physician.

PubMed CentralRead more →

Stage IIIA double ALK-fusion lung adenocarcinoma: major pathological response to neoadjuvant alectinib

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: ALK-rearranged lung adenocarcinoma with both ELMOD3-ALK and EML4-ALK fusions. CEA/NSE/CA19-9 decreased after alectinib.

As of April 2025, he had continued alectinib for 4 years after surgery, with more than 48 months of disease-free survival, no recurrence, and no serious drug-related toxicity.

PubMed CentralRead more →

Stage 4 SMARCA4-deficient lung cancer: ongoing treatment response

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: SMARCA4-deficient lung cancer with BRG-1 loss, CK/CK7 positive, Ki-67 >40%. CEA

Metastatic Site: sigmoid colon, left adrenal gland

After colon metastasis surgery, continued radiotherapy, and later gemcitabine/nedaplatin/bevacizumab/camrelizumab for adrenal metastasis, the cancer showed a favorable response with no further recurrence or new metastasis reported.

PubMed CentralRead more →

Clinical Stage IB lung adenocarcinoma: no recurrence after thoracoscopic lobectomy and pneumatocele repair

Patient Info: Anonymized, Male, 60s | Stage I

Biomarkers: No molecular biomarkers reported; tumor markers were normal: CEA 2.1 ng/mL, SCC antigen 1.5 ng/mL, cytokeratin 19 fragment 0.9 ng/mL

As of March 2025, the patient had no recurrence after thoracoscopic left lower lobectomy for lung adenocarcinoma; postoperative pneumatocele-related air leak resolved with reinforcement and adhesive therapy.

PubMed CentralRead more →

Localized lung adenocarcinoma: disease-free after CT-guided marking and VATS wedge resection

Patient Info: Anonymized, Female, 50s

Biomarkers: No lung molecular biomarkers reported; prior malignant melanoma had BRAF codon 600 mutation

As of March 2025, she remained free of signs of lung cancer recurrence after CT-guided marking, VATS wedge resection, and mediastinal lymph node sampling.

PubMed CentralRead more →

Metastatic lung adenocarcinoma: complete remission on nivolumab complicated by immune-mediated diabetes

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Lung tumor: EGFR wild type, ALK rearrangement not detected. Immune-mediated diabetes: islet/GAD antibodies negative and C-peptide undetectable.

Metastatic Site: brain (cerebellum and occipital lobe); liver

As of March 2025, serial CT and MRI scans through October 2023 showed no evidence of oncologic disease after nivolumab, while immune-mediated diabetes was controlled with basal-bolus insulin.

PubMed CentralRead more →

ALK-Fusion Small Cell Lung Cancer Responding to Ensartinib

Patient Info: Anonymized, female, 70+ | Stage I

Biomarkers: EML4-ALK fusion; TP53 and RB1 mutations; PD-L1 at least 50%

The recurrent hilar lymph nodes shrank on ensartinib, and treatment was still ongoing at the January 2025 cutoff with more than 12 months without progression.

PubMed CentralRead more →

Stage IV KRAS Lung Cancer: Rosemary's Patient Story

Patient Info: Rosemary Conway, female, 60s | Stage IV

Biomarkers: KRAS mutation

After 14 months on daraxonracib in a clinical trial, Rosemary’s Stage IV lung cancer had stopped growing and she had returned to walking and lifting weights.

Dana-FarberRead more →

Non-Small Cell Lung Cancer: Donnita's Survivor Story

Patient Info: Donnita, Female, 60s

Biomarkers: Biomarker testing requested through Foundation Medicine; results not reported

Donnita had Stage IA2 non-small cell lung adenocarcinoma found by screening and treated with robotic wedge resections with clear margins. As of March 2025, she was living after early-stage surgery with fear of recurrence and ongoing advocacy.

The Patient StoryRead more →

EML4-ALK lung cancer: complete remission on alectinib for 4 years

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EML4-ALK fusion

Metastatic Site: brain

Alectinib produced complete remission for nearly 4 years; after grade 3 colitis/ulcers, she switched to ceritinib and maintained stable tumor control without recurrent intestinal ulcers or colitis.

PubMed CentralRead more →

EGFR-Mutant Lung Adenocarcinoma That Transformed to Small Cell Lung Cancer

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain, adrenal gland, liver, thyroid

The cancer progressed after small-cell transformation with adrenal, thyroid, liver and brain involvement, and she died 52.7 months after the original diagnosis from disease progression and organ failure.

PubMed CentralRead more →